UBS upgraded CVS Health Corp. to Buy from Neutral and raised its 12-month price target to $79 from $67, citing improving operations across the pharmacy chain’s businesses. Lead analyst Kevin Caliendo pointed to two consecutive quarters of better-than-expected results and early evidence that fixes in the company’s Healthcare Benefits segment are taking hold. UBS now models a 14% compound annual growth rate for CVS’s earnings per share over the next several years. The call lifted CVS shares roughly 2% in morning New York trading to about $68.60, narrowing the gap between the current price and the new target as investors welcomed signs of a sustained recovery.